On Demand CE: Pharmacology Course 2018: The Cardiac Patient with Obesity, Diabetes, or Atrial Fib

Pharmacology Course 2018: The Cardiac Patient with Obesity, Diabetes, or AFib

Clinical management of chronic cardiovascular disease is a key component of the work of advanced practice nurses and RNs in the cardiology and primary care settings. PCNA develops an annual pharmacology CE program to meet the clinical practice and recertification needs of these clinicians.

This year, course director Cindy Lamendola, MSN, ANP-BC has developed a curriculum that includes a comprehensive approach to Pharmacology in:
  1. Medications Management of Excess Weight and Co-Morbid Conditions 
  2. Anti-Hyperglycemic Therapies: Improving CVD Outcomes 
  3. Medications to Manage Rate, Rhythm and Symptoms Associated with AFib and Flutter.
Those who satisfactorily complete this course will earn 7.0 CE contact hours of pharmacology. Independent self-paced pre and post course evaluation are included. 

Credit: 7.00 Pharmacology CE contact hours
Cost: $45 for members, $115 for non-members

Take this Course

Faculty:

  • Course Director: Cindy Lamendola, MSN, NP, FAHA, FPCNA
  • Melissa Davis, DNP, ANP-BC, CNS, CBN, CNOR, RNFA
  • T. Jennifer Walker, ANP-BC

Upon completion of this activity, participants will be able to: 

  • Review National Guidelines for the Management of Obesity and the recommendations regarding pharmacotherapy in relationship to behavioral interventions and surgical procedures.
  • List FDA approved medications for weight management and their approved dosing, schedule, adverse effects and contraindications.
  • Describe, using case examples, how to match patients with co-morbid conditions to safe and effective weight management therapies.
  • Describe the new challenge for cardiology in prescribing medications to manage diabetes as well as CVD. 
  • Review recent clinical trials of anti-hyperglycemic therapies, CV outcomes and impact on FDA indications. 
  • Discuss appropriate antihyperglycemic therapy selection, dose and potential side effects in selected case studies. 
  • List common medications used to control heart rate in patients with atrial fib and flutter along with appropriate dose, schedule, adverse effects and contraindications.
  • Describe the role of medications in cardioversion and maintenance of sinus rhythm in patients with atrial fib and flutter along with appropriate dose, schedule, adverse effects and contraindications. 
  • Review common symptoms associated with atrial fib and flutter and discuss the impact of heart rate and rhythm control therapies on these symptoms. 

Cindy Lamendola for the 2018 Pharmacology Preconference
Melissa Davis and T. Jennifer Walker for the 2018 Pharm Preconference
This educational activity is provided by the Preventive Cardiovascular Nurses Association (PCNA). PCNA is accredited by the American Association of Nurse Practitioners (AANP) as an approved provider of Nurse Practitioner continuing education, provider number 030602.